Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment

Figure 1 Inhibition ratio of hepatitis B virus covalently closed circular DNA (A) and DNA (B) following different treatments of HepG2. 2.15 cells. A: Hepatitis B virus covalently closed circular DNA (HBV cccDNA) was quantified with real-time polymerase chain reaction; B: Hepatitis B virus DNA (HBV DNA) was quantified with real-time polymerase chain reaction. Data are expressed as the mean ± SD from three individual experiments. ^aP < 0.05 vs lamivudine group.

Figure 2 Levels of hepatitis B surface antigen and hepatitis B e antigen following different treatments of HepG2. 2.15 cells. Sequential treatment reduced the levels of hepatitis B surface antigen (HBsAg) (A) and hepatitis B e antigen (HBeAg) (B) most strongly at 16 d in the treatment period. ^aP < 0.05 vs control group, ^cP < 0.05 vs lamivudine group, ^eP < 0.05 vs cytokine group.

Figure 3 Lamivudine pretreatment significantly reduces interferon-γ + tumor necrosis factor-α-mediated toxicity of HepG2. 2.15 cells. Percent cell survival was analyzed with the cell counting kit (CCK)-8 assay following exposure of HepG2.2.15 cells to the four treatments. Data are expressed as the mean ± SD from three individual experiments. ^aP < 0.05 vs control, ^cP < 0.05 vs lamivudine group, ^eP < 0.05 vs cytokine group.